



CONTINUING MEDICAL EDUCATION INFORMATION

MISSION

The purpose of the American Academy of Dermatology (AAD) CME Program is to provide members with opportunities for life-long learning and assistance in fulfilling their maintenance of certification and licensure requirements, thereby promoting excellence in the provision of dermatologic care.

DEFINITION OF CONTINUING MEDICAL EDUCATION

Continuing medical education consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession. The content of CME is that body of knowledge and skills generally recognized and accepted by the profession as within the basic medical sciences, the discipline of clinical medicine, and the provision of health care to the public. *Source: www.accme.org*

COMMERCIAL BIAS

A personal judgment in favor of a specific proprietary business interest of a commercial interest.

Source: www.accme.org

SCIENTIFIC ASSEMBLY COMMITTEE

** As of the November 19, 2021 planning meeting.*

David Ozog, MD
Tammie Ferringer, MD
Moise Levy, MD
Kathryn Schwarzenberger, MD
Robert Sidbury, MD, MPH
Hensin Tsao, MD
Marta Van Beek, MD, Secretary-Treasurer
Daniel Bennett, Assistant Secretary-Treasurer
Kenneth Tomecki, MD, President

Mark Kaufmann, MD, President-Elect
Bryan Anderson, MD, Chair, Council on Education
Julia Wu, MD, Chair, Education Research Committee
Kim Yancey, MD, Chair, Named Lectureship Task Force
Paola Pasquali, MD, Chair, International Affairs Committee
Dhwani Mehta, MD, Young Physician's Committee Representative

STATEMENT OF NEED

The AAD VMX is planned to comprehensively address the nine content areas within the Dermatologic Core Curriculum and provide dermatologists and other dermatology health care professionals with high quality educational opportunities for the optimization of dermatologic knowledge, competence and performance.

TARGET AUDIENCE

The target audience of the AAD VMX are dermatologists and others involved in the delivery of dermatologic care.

GLOBAL LEARNING OBJECTIVES

This comprehensive activity provides learners with opportunities to:

- Review and apply basic knowledge and skills in medical dermatology, dermatologic surgery, pediatric dermatology, and dermatopathology.
- Update their knowledge about recent advances in the diagnosis, management and treatment of diseases of the skin, hair, nails, and mucous membranes.

- Assess the relationship of evidence-based diagnostic approaches and therapies with new dermatologic treatment developments.

NOTE: Each session has its own specific learning objectives which are included within each session in VMX.

DISCLOSURES

PLANNER DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)

The following Scientific Assembly Committee members and staff reported they have no relationship(s) with commercial interest(s) to disclose relevant to the content of this CME activity:

- Bryan Anderson, MD, FAAD
- Daniel D. Bennett, MD, FAAD
- Tammie Ferringer, MD, FAAD
- Cari Lamberg
- Tammi Matillano
- Dhwani S. Mehta, MD, FAAD
- Timothy A. Moses, CMP
- Jennifer Thompson
- Kenneth J. Tomecki, MD, FAAD
- Julia Wu, MD
- Candi Zabiegala

The following Scientific Assembly Committee members and staff reported they do have relationship(s) with commercial interest(s) to be disclosed to learners:

Planner	Commercial Interest	Role	
Mark D. Kaufmann, MD, FAAD	Biofrontera AG	Consultant / Fees	
	Castle Biosciences, Inc	Consultant / Fees	
	Clarify Medical, Inc.	Consultant / Fees	
	DermTech Inc.	Advisory Board / Fees	
	Galderma USA	Consultant / Fees	
	Klara/Goderma, Inc.	Consultant / Stock Options	
	MediWound	Consultant / Fees	
	Modernizing Medicine	Consultant / Stock	
	MoleSafe, Inc.	Other / Fees, Other / Stock	
	Ortho Dermatologics	Consultant / Fees	
	Rise Healthcare Tech	Advisory Board / Stock Options	
	SciBASE	Consultant / Fees	
	Sun Pharmaceutical Industries, Ltd.	Consultant / Fees	
	UCB	Consultant / Fees	
	Verrica Pharmaceuticals, Inc	Consultant / Fees	
	Moise L. Levy, MD, FAAD	Abeona Therapeutics	Advisory Board / Fees
			Advisory Board / Fees, Investigator / Grants/Research Funding
Castle Creek Pharmaceuticals		Investigator / Grants/Research Funding	
Fibrocell Sciences		Investigator / Grants/Research Funding	
Janssen Pharmaceuticals, Inc		Investigator / Grants/Research Funding	
Krystal Biotech, Inc		Investigator / Grants/Research Funding	
		Data Safety	
Mayne Pharma Group		Monitoring Board / Fees	
Novan		Data Safety Monitoring Board / Fees	
		Advisory Board / Fees, Investigator / Grants/Research Funding	
	Regeneron	Grants/Research Funding	
	UpToDate, Inc.	Other / Salary	
David M. Ozog, MD, FAAD	Biofrontera AG	Investigator / Grants/Research Funding	

	Galderma USA Michelson Diagnostics miRagen Therapeutics, Inc. Regeneron Sanofi Genzyme Sciton, Inc.	Investigator / Grants/Research Funding Investigator / Grants/Research Funding Investigator / Grants/Research Funding Speaker / Honoraria Speaker / Honoraria Investigator /Equipment Advisory Board / No Compensation Received Other / Patent royalties or other compensation for Intellectual Property Rights
Paola Pasquali, MD	Dermosight Springer Science & Business Media	
Kathryn Schwarzenberger, MD, FAAD	Pfizer Inc. Pretel, Inc.	Data Safety Monitoring Board / Fees Founder / No Compensation Received
Robert Sidbury, MD, MPH, FAAD	Galderma Global Galderma USA Leo Pharma Inc Pfizer Inc. Regeneron Pharmaceuticals, Inc.	Speaker / Honoraria Investigator / Grants/Research Funding Advisory Board / Honoraria Advisory Board / Honoraria Investigator / No compensation Received
Hensin Tsao, MD, PhD, FAAD	Epiphany Dermatology Lazarus AI Massachusetts General Hospital Ortho Dermatologics UpToDate, Inc.	Advisory Board / Honoraria Consultant / Honorarium Employee / Salary Board of Directors / Honoraria Other / Honoraria
Marta Jane Van Beek, MD, MPH, FAAD	AbbVie Becton Dickinson Johnson and Johnson Moderna Therapeutics Pfizer Inc. Regenx Vertex Pharmaceuticals, Inc.	Stockholder / No Compensation Received Stockholder / No Compensation Received Stockholder / No Compensation Received Stockholder / No Compensation Received Stockholder / No Compensation Received Stockholder / No Compensation Received Stockholder / No Compensation Received
Kim B. Yancey, MD FAAD	UpToDate, Inc	Other / Honorarium

FACULTY DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)

It is the policy of AAD that all faculty participating in a CME-certified activity are required to disclose to AAD and to learners relevant financial relationships that they or their first-degree relatives (spouse, parent, sibling, or child) have with any commercial interest(s). "Relevant financial relationships"¹ include financial relationships in any amount occurring within the past 12 months that create a conflict of interest². Typically, such

¹ **Relevant Financial Relationships:** The ACCME defines "relevant financial relationships" as financial relationships in any amount occurring within the past twelve months that create a conflict of interest. *Source: www.accme.org.*

² **Conflict of Interest:** When an individual's interests are aligned with those of a commercial interest the interests of the individual are in "conflict" with the interests of the public. *Source: www.accme.org*

relationships would be with companies that sell health care products or services that are consumed by or used in the treatment of patients. The intent of this disclosure is not to prevent participation in CME-certified educational activities by individuals with a relevant financial relationship with commercial interest(s), but rather to provide learners with information on which they can make their own determination whether or not said relationship(s) influenced the content of the educational activity.

Faculty disclosure information is located each individual session. Faculty have been asked to also make a verbal disclosure at the start of their presentations supplemented by a disclosure slide in order to verify the accuracy of the disclosure information posted in the session and ensure their disclosure information is shared with the learners PRIOR to the presentation taking place.

RESOLUTION OF CONFLICTS OF INTEREST

In accordance with the ACCME Standards for Commercial Support of CME, the American Academy of Dermatology has implemented mechanisms, prior to the planning and implementation of this CME activity, to identify and mitigate conflicts of interest for all individuals in a position to control the content of this CME activity.

UNAPPROVED USE DISCLOSURE

The American Academy of Dermatology requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label (not approved for the indications being discussed), unlabeled (not approved for any indications), experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these products/procedures. If you have questions, contact the medical affairs department of the manufacturer for the most recent approval information. Faculty for this activity will be discussing information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

INDEPENDENCE IN CME

The mission of the Academy's continuing medical education program is to improve patient care and health care outcomes by maintaining, developing and enhancing medical knowledge, patient care, interpersonal and communication skills and professionalism. As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME) and in support of this mission, the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias.

The Academy employs several strategies to ensure these standards will be met. The planning committee members submit and consider their own disclosure information and recuse themselves from planning educational activities should they have conflicts related to the subject area presented. When developing an educational program, the planning committee reviews applications and disclosure of interest forms, along with needs assessment and evaluative data from past activities in order to develop programming. Potential participants are sent detailed guidelines that provide direction on necessary components to ensure independence in continuing medical education activities and to resolve conflict.

CONTENT VALIDATION

Academy-sponsored educational activities are designed to promote improvements or quality in health care and not promote a specific proprietary business interest or a commercial interest. Presentations and related materials must be based on scientific methods generally accepted by the medical community.

Presentations should be evidence-based and discuss the validity of the evidence upon which they base the opinion(s) (see Sackett et al, BMJ 1996;312:71-2). This ensures the audience that the recommendations are supported by the evidence and contributes to management of any potential conflicts of interest. Further, if the presentation includes discussion of unlabeled or investigational use of a commercial product, this also must be disclosed to the participants. CME must give a balanced view of therapeutic options. Use of generic names will contribute to this impartiality.

If CME educational material or content includes trade names, trade names from several companies should be used where available, as opposed to using trade names from just a single company. Educational materials such as slides, abstracts, and handouts cannot contain any advertising or product-group messages.

OUTCOMES MEASUREMENT

Several methods of evaluation are utilized in assessing the educational program. Session directors, speakers, and attendees are all given the opportunity to evaluate the educational content and speaker performance. Included in this process are measures to rate the success of the Academy's policies regarding independence in continuing medical education activities with particular focus on the absence of commercial bias.

In addition, the Academy may review speaker presentations. These data are only used to determine effectiveness of the Academy's policies and procedures regarding disclosure. Should it be determined that a member of the Academy's educational program violated the Academy's "Policy to Ensure Independence in Continuing Medical Education," the individual may not be asked to participate in future educational programs.

DISCLAIMER

The American Academy of Dermatology is not responsible for statements made by faculty. Statements or opinions expressed in this program reflect the views of the faculty and do not reflect the official policy of the American Academy of Dermatology. The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to the diagnostic, management and treatment options of a specific patient's medical condition.

ACCREDITATION

The American Academy of Dermatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA PRA CATEGORY 1 CREDIT™ DESIGNATION

The American Academy of Dermatology designates this other activity for a maximum of **107.75 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

WHAT YOU NEED TO DO TO CLAIM CME CREDIT

CME credit is awarded based on participation in the learning activities. CME credits can be claimed online at vmx2022.aad.org or in the meeting mobile app. Credit is calculated on a ¼-hour basis and will be reflected on member transcripts within two weeks after the meeting.